Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the research and development team will present the clinical design for an ongoing study of VS-6063 and preclinical data on the dual PI3K/mTOR inhibitor VS-5584 at the American Society of Clinical Oncology Annual Meeting being held May 31 – June 4, 2013, at McCormick Place in Chicago, IL. Research on the FAK and PI3K/mTOR signaling pathways has revealed critical roles for each in cancer stem cell survival and disease progression.
Help employers find you! Check out all the jobs and post your resume.
